key: cord-0781326-ukcz6i65
authors: Maggiorani, Damien; Beauséjour, Christian
title: Senescence and Aging: Does It Impact Cancer Immunotherapies?
date: 2021-06-22
journal: Cells
DOI: 10.3390/cells10071568
sha: d5e5aa5254caa3673ad41fd6bcc563990b404ee6
doc_id: 781326
cord_uid: ukcz6i65

Cancer incidence increases drastically with age. Of the many possible reasons for this, there is the accumulation of senescent cells in tissues and the loss of function and proliferation potential of immune cells, often referred to as immuno-senescence. Immune checkpoint inhibitors (ICI), by invigorating immune cells, have the potential to be a game-changers in the treatment of cancer. Yet, the variability in the efficacy of ICI across patients and cancer types suggests that several factors influence the success of such inhibitors. There is currently a lack of clinical studies measuring the impact of aging and senescence on ICI-based therapies. Here, we review how cellular senescence and aging, either by directly altering the immune system fitness or indirectly through the modification of the tumor environment, may influence the cancer-immune response.

Improved life conditions and medical innovations have led to an increased lifespan [1] . While the risk of developing cancer rises in patients over 60 years old, cancer incidence actually decreases at the age of 85 for reasons that are not fully understood but that likely involve the decline in cells' proliferative potential [2] [3] [4] . The accumulation of senescent cells plays an important role in the risk of developing several age-related diseases, including cancer [5, 6] . However, it is still unknown whether cellular senescence affects the efficacy of anticancer treatments and, in particular, the ability of cancer cells to evade the immune system [7] . This question is increasingly important with the emergence of promising new immunotherapy treatments. In this review, we highlight recent observations suggesting that aging and senescence can alter immune cell fitness and, ultimately, have an impact on the efficacy of cancer treatments.

The senescence phenotype is characterized by an irreversible cell cycle arrest and was first described by Moorhead and Hayflick in 1961 [8] . Dimri and Campisi then identified the first marker, which they named the senescence-associated-β galactosidase or SA-βgal [9] . Since then, the field has widely evolved, and several other characteristics describing senescent cells have been identified, although none can be referred to as a universal marker [10, 11] . Most often, it is best to identify a senescent cell through a combination of the following features: SA-β-gal, expression of a cyclin-dependent kinase inhibitor (CDKi) such as p16 and/or p21 [12] , persistent telomeric DNA damage [13] , the formation of a heterochromatin foci [14] , a senescence-associated secretory phenotype (SASP) composed mostly by proinflammatory cytokines (IL-6 and IL-8), growths factors (VEGF and GM-CSF) and matrix-metalloproteinase (MMP) [15] , and the accumulation of lipofuscin deposits [16] . The senescence phenotype can be engaged by a variety of stimuli such as telomeres erosion, leading to replicative exhaustion [17] , exposure to genotoxic stressors (chemotherapy and

Here, we will discuss how we think aging and senescence can predominantly interfere with the efficacy of immunotherapies [65] . The efficacy of ICI is largely dependent on the tumor microenvironment (TME), which is composed by immune and nonimmune cells, such as cancer-associated fibroblasts (CAFs) and tumor-infiltrated leukocytes (TILs). CAFs shape and build up the tumor, whereas TILs, defined by a large family of lymphocytes and myeloid cells, have a double-edged role by either eliminating and/or feeding the tumor growth.

The identification of CAFs is challenging given their high heterogeneity and the lack of fibroblast-restricted markers [66] . The accumulation of CAFs in the TME is a negative prognosis, since they are a source of immunosuppressive cytokines such as IL-6, CXCchemokine ligand (CXCL), and TGFβ [67] . CAFs are mainly derived from bone marrow progenitors [68] and the surrounding fat tissue [69] . Several components of the SAPS (i.e., the TGFβ family ligands, IL-6, IL-1, and CXCL-1) can contribute to the formation of CAFs [70] [71] [72] [73] . Thus, the accumulation of senescent cells and the secretion of SASP within the TME may enhance the recruitment or the formation of CAFs and diminish the efficacy of ICI by consolidating an immunosuppressive environment [74] .

How aging shapes the phenotype of CAFs is elusive and needs to be further investigated. Intrinsically, CAFs and senescent fibroblasts share common features, and the differences between them remain difficult to define. For example, CAFs and senescent fibroblasts express SA-β-gal and accumulate DNA damage [75] . The first demonstration that senescent fibroblasts, just like CAFs, have an impact on tumor growth came 20 years ago by Krtolica and Campisi, who showed that senescent human fibroblasts, when co-injected with pre-tumorigenic cell lines, boost tumor growth [76] . One limitation from this important study is that human cells had to be injected in nude mice and, thus, in the absence of most immune cells. Since then, the work by Ruhland and Stewart using immune-competent mice showed that murine senescent stromal cells can increase the recruitment of suppressive myeloid cells and promote tumor growth [77] . Similarly, senescent fibroblasts through the secretion of IL-6/IL-8 and amphiregulin were shown to favor the differentiation of monocytes into proinflammatory M2 macrophages and to drive the expression of PD-L1 in tumor cells, respectively [75, 78] . In addition, CAFs stimulated with proinflammatory cytokines, such as IL-1α, IL-1β, and TNFα, tend to adopt a senescent state that favors tumor cell resistance to apoptosis and dissemination [73] . Whether human senescent fibroblasts, through their SASP, have positive or negative impacts on the tumor immune response is not clear at this point. To answer that question, one will need to use newly developed mouse models where tumor cells can be rejected in humanized mice [79] . While not the topic of this review, several studies have shown that cancer treatment-induced senescence has a major impact on the rejection of murine tumors by immune cells [80] . Interestingly, the systemic elimination of senescent cells was shown to decrease mammary tumor metastasis and chemotherapy-associated fatigue [81] . In summary, manipulating CAFs and senescent cells appears to be a promising strategy to decrease tumor growth. This will be better done when we learn more on how aging and senescence impact the accumulation of CAFs and shape their secretion profile.

TILs are mostly constituted of T cells and myeloid cells, and they play an important role in the tumor immune response. Yet, these cells have completely different functions within the TME. As we age, the number of circulating T cells tends to decrease, while there is no significant modification in the number of B cells [82] . Thymic involution, along with the architectural and functional alterations during aging, have been abundantly described to explain the reduction of circulating naïve T cells [83, 84] . In addition, several publications showed a decline in the T-cell receptor (TCR) repertoire in aged naïve T cells, which can lead to an impaired immunity [84] [85] [86] . Alterations in bone marrow hematopoiesis during aging is associated with the accumulation of circulating myeloid cells, a process called myeloid skewing [40, 87, 88] . Lymphocytes (mostly CD8-positive T cells) are activated in secondary lymphoid organs (i.e., the spleen and lymph nodes) by specialized antigen-presenting cells (APC) and, then, are recruited within tumors. These cytotoxic CD8 lymphocytes are the main cells responsible for tumoral clearance, and their accumulation is associated with a good prognosis. However, activated T cells often become exhausted within tumors, a state characterized by the sustained expression of inhibitory receptors (i.e., PD-1 and CTLA-4) and associated with tumor immune resistance [89] . In mouse spleens, the number of highly exhausted T cells, which fail to proliferate after TCR activation and display enhanced IL-10 production, was shown to gradually increase with age [90] . Interestingly, the work by Sceneay et al. showed that blocking both PD-L1 and CTLA-4 was less efficient in old (>12 months old) compared to young mice in a triple-negative breast tumor model [91] . Mechanistically, it was shown that CD8 T cells in aged mice had a higher level of exhaustion and a diminished production of IFNγ. Interestingly, upon activation, T cells isolated from young mice were shown to exhibit a core transcriptional profile that was not as strongly activated and more heterogeneous in T cells collected from old mice [92] . This suggests that intrinsic transcriptional differences occur in T cells with age. Whether these differences were mediated by T-cell exhaustion or senescence, two processes regulated independently, was not investigated [93] . Overall, whether senescence and aging have an impact on the efficacy of ICI to reinvigorate exhausted TILs remains to be determined.

A big question in the field is whether T cells truly become senescent during aging and if it affects their functions [94] . The first evidence came when the expression of the Cells 2021, 10, 1568 5 of 18 senescence marker p16 was found increased in circulating T cells collected from both aged mice and humans [95, 96] . However, these studies did not reveal the fraction of T cells expressing p16. This information came later using a reporter mouse model that allowed the tracking of p16-positive cells by flow cytometry, where it was shown that less than 1% of the circulating T cells expressed p16 in aged mice [25] . This was 5-10 times less than the frequency observed in cartilage and fat progenitor cells. On the opposite hand, a recent study showed that the frequency of human T cells expressing senescence markers could be as high as 60% in patients over 60 years old. These results were mostly based on the expression of SA-β-gal by flow cytometry, and whilst sorted positive cells expressed other markers of senescence, these were not quantified at the single-cell level [59] . Importantly, these senescent T cells were shown to be impaired in their ability to proliferate. The discrepancy in the estimated frequency of senescent T cells between these two studies can be explained by the difference between mice and humans and by the methodology used. Indeed, it is possible that the sensitivity of the reporter mouse model, based on Td-Tomato expression, although better than all other models available, underestimates the frequency of p16-expressing cells. Using an irradiation-induced premature aging mouse model, our group also demonstrated that T cells collected from the spleen had a higher p16 expression, but we found these cells to preserve their proliferative capacities in vitro. Only when T cells were mixed with full splenocytes, collected from an irradiated mouse, was their proliferation delayed, highlighting the importance of the splenic microenvironment [97] .

Others have defined senescent T cells as a population expressing CD45RA and CD57 but deficient for CD28/CD27, a phenotype delineating T-effector memory (Temra) cells in humans [98] . This subpopulation of T cells was shown to increase with age; to overexpress several SASP-related genes (i.e., like IL-10, TNFα, and IFNγ); and to proliferate less than their double-negative counterparts [99] [100] [101] . These cells, often referred to as senescentlike, were also found to be associated with several aged-related pathologies, such as type 2 diabetes [102] , acute heart failure [103] , and acute proinflammatory situations like COVID-19-exposed patients [104] . In opposition, others demonstrated that human CD57-positive and CD57-negative T cells exhibit similar proliferation properties [105] . Altogether, it appears that T cells undergo cellular aging and senescence and that their functions are intrinsically or extrinsically diminished [94] . Keeping in mind that human T cells collected from a 60-year-old donor already displayed high levels of senescence markers, it is easy to speculate that the efficacy of ICI is likely already diminished at that age [59] .

Tregs are a subpopulation of immunosuppressive CD4 T cells that are often defined by the expression of the transcription factors Foxp3 and CD25 [106] . In aged mice, the number of Tregs increases, and these cells are more effective at suppressing the proliferation of effector T cells compared to Treg cells collected from young mice [107] . Moreover, Tregs isolated from aged mice overexpress IL-10 and strongly suppress the expression of CD86 in DC, an essential receptor for antigen presentation [107, 108] . On the opposite hand, a recent manuscript showed that Tregs isolated from aged mice, expressing the p16 and p21 senescence markers, were less effective at decreasing T-cell activation compared to Tregs isolated from young mice [109] . We believe this discrepancy could be associated with the difficulty in identifying Tregs with current markers and the different methods used to assess T-cell activation. Interestingly, in a model of B16-resistant tumors, Treg depletion in 19-24-month-old mice partially improved the efficacy of the CTLA-4-but not PD-L1-blocking antibodies [58] . Hence, the impact of senescence and aging on Tregs remains much debated at this point.

Macrophages are myeloid specialized cells that, as part of the adaptive immune response, can phagocyte and present tumor antigens. During aging, macrophages are shown to express markers of senescence (i.e., p16 expression and SA-β-gal) [25] . Strikingly, these senescent macrophages exhibit a higher phagocytosis capacity and a decreased 5-Ethynyl-2 -deoxyuridine (EdU) incorporation. In mice, the injection of alginate beads into the peritoneal cavity leads to the accumulation of senescent-like macrophages positive for SA-β-gal and p16 [110, 111] . In the TME, tumor-associated macrophages (TAM) promote neovascularization, tumor growth, and metastasis through cytokines (i.e., IL-6, IL-8, and IL-10) that clearly overlap with the SASP [112] . To our knowledge, only one study has demonstrated the detrimental role of TAM during aging: it was shown that TAMs pushed mesothelioma tumors to grow faster in aged vs. young mice [113] . Blocking these TAMs using F4/80 antibodies could restore the efficacy of an IL-2/anti-CD40-based immunotherapy in aged mice.

Like macrophages, there is no clear evidence showing that dendritic cells (DC) can express classical senescence markers. However, DC isolated from aged mice were shown to exhibit an impaired capacity to cross-present antigens to CD8-positive T cells in vitro [114] . This may be linked to the observation that DC collected from aged mice have a defect in their antigen-processing machinery. In humans, a study showed that DC isolated from old donors (over 65 years old) secrete more SASP-related cytokines (IL-6 and TNFα) compared to the same cells isolated from younger donors (range 21-30 years old) [115] . Overall, there is little evidence describing and characterizing the senescence state of macrophages or DC. Hence, their impact on aging and on the efficacy of ICI treatments remains to be determined.

Similar to macrophages, tumor-associated neutrophils play an important role in the tumor immune response, and their accumulation is associated with a poor prognosis [116, 117] . Neutrophils have an impact on many mechanisms, including promoting inflammation, extracellular matrix remodeling, angiogenesis, metastasis, and immunosuppression [116] . It is believed neutrophils release reactive oxygen species that can inhibit T-cell activation and express ligands that activate immune checkpoints [118] [119] [120] . Given their short half-lives, there is no evidence that neutrophils adopt a senescence phenotype. However, evidence suggests that neutrophils may be influenced by the SASP. Indeed, it is known that neutrophils can undergo cell death in the form of NETosis, where the nuclear DNA of neutrophils is extruded and projected into the surrounding tissue [121] . It was shown that the release of neutrophil extracellular traps (or NETs) within a tumor, by obstructing contact with immune cells, protect malignant cells [116, 122] . A recent publication highlighted the roles of CXCR1 and CXCR2 in the production of NETs [123] . Interestingly, their ligands, CXCL8 (IL-8) and CXCL1 (GRO1/KC), respectively, are two major SASP factors [124] . Based on this information, we believe senescent cells within the TME, through their SASP, could induce the release of NETs and interfere with tumor immune clearance.

Myeloid-derived suppressive cells (MDSC) represent a subpopulation of neutrophils. MDSC originate from the incomplete differentiation of common myeloid progenitors in the presence of inflammatory cytokines (i.e., IL6, TNFα, and MCP-1) within the TME. MDSC can be separated into two major subpopulations, monocytic-MDSC and granulocytic-MDSC, classified according to their origin from monocytic or granulocytic lineages, respectively [125, 126] . Despite distinct origins, MDSC play an important role during tumorigenesis, as they have the ability to suppress T-cell activation by using several mechanisms, such as expressing Arginase1, CD39/73, IL-10, or the release of ROS [127] . MDSC accumulate within tissues and tumors during aging, though there is no evidence that they become more immunosuppressive [128, 129] . Yet, the expression of p16 and p21 in MDSC was shown to stimulate the expression of the CX3CR1 chemokine receptor, which led to enhancing chemotaxis and the recruitment of MDSC into tumors [130] . The recruitment of MDSC expressing p16 is consistent with a previous report describing the presence of BM-derived p16-expressing cells in the TME [131] . However, it was noted that these MDSC are very unlikely to be in a state of cellular senescence, as they did not have other senescence markers [130] . Whether MDSC from aged mice express higher levels of p16 was not evaluated.

In the same lines, increased tumor growth in older mice (2 vs. 12 months old) was associated with the accumulation of MDSC [132] . Mechanistically, it was shown that MDSC within the tumors of older mice had higher levels of Arginase1, a known inhibitor of proliferation. Others have reported a significant increase in the overall percentage of MDSC present in the bone marrow and spleens of aged compared to young animals [133] . However, the functions of these cells appeared not to be compromised in aged mice. The depletion of Tregs efficiently delays B16 tumor growth in young, but not in aged, mice, an effect that was mediated by an increase in the recruitment of MDSC [134] . However, the mechanistic link between Tregs and the recruitment of MDSC was not studied. Interestingly, an increased level of circulating MDSC was observed in melanoma patients and associated with a resistance to anti-CTLA-4 therapy [135] . In breast cancer patients, the level of circulating MDSC also correlated with the clinical stage and chemotherapy treatment efficacy [136] . Overall, it appears that phenotypic changes and an increase in the number of MDSC in aged mice may compromise the efficacy of ICI.

An increase in the baseline tumor size is associated with a resistance to ICI and represents a negative prognostic factor for lung cancer and melanoma [137, 138] . As discussed above, considering the overall age-related immunosuppression, it would be expected for tumors to grow faster in aged recipients. However, the literature is showing that the tumor growth rate in young vs. aged mice is largely divergent. For one, B16 melanoma, Engelbreth-Holm-Swarm, and BSC9AJ2 tumors were shown to grow faster in young vs. old mice [64, [139] [140] [141] . Another study confirmed a delayed tumor growth in older compared to younger mice using several tumor cell lines (MCA-38, B16, and 4T1) [142] . In this study, an increased CD8 T-cell infiltration in MCA-38 tumors was attributed to an overexpression of the integrin VLA-4 (CD49d) and considered as a possible mechanism for reduced tumor growth. Finally, the growth of Met1, but not 4T1, tumors (and yet, two mammary cell line tumors) were shown to be delayed in older mice [91] . Several other studies demonstrated no effect of aging on tumor growth. For examples, the growth rates of B16 and TRAMP-C2 melanoma tumors were not reduced in old mice [134, 140] . Nonetheless, another study showed that the TRAMP-C2 cell line grows faster in older than in younger mice, an effect that may be explained by an elevated number of TAMs and a higher extracellular matrix remodeling capacity [143] . Finally, two studies showed that B16 and TS/A tumor cells injected in mice tend to growth faster with age [58, 132] . Furthermore, the growth of AE17 mesothelioma tumors was increased in aged mice, an effect associated with an increase in tumor-infiltrating macrophages [113] . The reasons for such discrepancies are not clear. Variations in the number of cells injected, the site of injection, and the age of mice, together with the in vitro genetic drifting of tumor cell lines over the years, may account for it (Table 1) . Overall, these results suggest that the age of the host plays an important role in the tumor growth rate. We speculate that reduced growth rates in older patients may be a confounding effect, as it compensates for the reduced immune cell fitness in the overall impact of age in the success of immunotherapy treatments. in older patients may be a confounding effect, as it compensates for the reduced immune cell fitness in the overall impact of age in the success of immunotherapy treatments. in older patients may be a confounding effect, as it compensates for the reduced immune cell fitness in the overall impact of age in the success of immunotherapy treatments. 

The administration of senolytic drugs is a promising strategy to prevent age-related pathologies. Two of the most tested senolytic treatments, D + Q and ABT263 (navitoclax), were, in fact, initially evaluated for their ability to kill tumor cells [144] [145] [146] . ABT263 has been in clinical trials, mostly for blood cancers, where it showed a limited effectiveness and severe treatment-induced thrombocytopenia [147, 148] . This led to the development of the analog venetoclax, which limits the occurrence of thrombocytopenia but is unfortunately ineffective as a senolytic drug [149] . Nonetheless, the repurposing of these drugs (perhaps at lower doses to limit the major side effects) or using one of the many novel senolytic drugs currently in development could, by eliminating senescent cells, reinvigorate immune cells and enhance the efficacy of immunotherapies. Few studies so far have explored the possibility of combining senolytic drugs with classical chemotherapy treatments. For one, the combination of D + Q with doxorubicin was shown mostly ineffective at further reducing tumor growths, as D + Q treatments were unable to eliminate doxorubicin-induced senescent cells [150] . However, it is likely that D + Q was injected too early (2 days) after the injection of doxorubicin, leaving no time for the induction of the senescent phenotype. In another study, ABT263 was used in combination with poly (ADP-ribose) polymerase 1 inhibitors (PARPi). This proved to be effective at reducing the growth 

The administration of senolytic drugs is a promising strategy to prevent age-related pathologies. Two of the most tested senolytic treatments, D + Q and ABT263 (navitoclax), were, in fact, initially evaluated for their ability to kill tumor cells [144] [145] [146] . ABT263 has been in clinical trials, mostly for blood cancers, where it showed a limited effectiveness and severe treatment-induced thrombocytopenia [147, 148] . This led to the development of the analog venetoclax, which limits the occurrence of thrombocytopenia but is unfortunately ineffective as a senolytic drug [149] . Nonetheless, the repurposing of these drugs (perhaps at lower doses to limit the major side effects) or using one of the many novel senolytic drugs currently in development could, by eliminating senescent cells, reinvigorate immune cells and enhance the efficacy of immunotherapies. Few studies so far have explored the possibility of combining senolytic drugs with classical chemotherapy treatments. For one, the combination of D + Q with doxorubicin was shown mostly ineffective at further reducing tumor growths, as D + Q treatments were unable to eliminate doxorubicin-induced senescent cells [150] . However, it is likely that D + Q was injected too early (2 days) after the injection of doxorubicin, leaving no time for the induction of the senescent phenotype. In another study, ABT263 was used in combination with poly (ADP-ribose) polymerase 1 inhibitors (PARPi). This proved to be effective at reducing the growth of ovarian and breast tumors [151] . Hypothetically, we believe that the beneficial effect of a senolytic treatment in aged patients could help at different levels ( Figure 1 ). For one, the Oh 

The administration of senolytic drugs is a promising strategy to prevent age-related pathologies. Two of the most tested senolytic treatments, D + Q and ABT263 (navitoclax), were, in fact, initially evaluated for their ability to kill tumor cells [144] [145] [146] . ABT263 has been in clinical trials, mostly for blood cancers, where it showed a limited effectiveness and severe treatment-induced thrombocytopenia [147, 148] . This led to the development of the analog venetoclax, which limits the occurrence of thrombocytopenia but is unfortunately ineffective as a senolytic drug [149] . Nonetheless, the repurposing of these drugs (perhaps at lower doses to limit the major side effects) or using one of the many novel senolytic drugs currently in development could, by eliminating senescent cells, reinvigorate immune cells and enhance the efficacy of immunotherapies. Few studies so far have explored the possibility of combining senolytic drugs with classical chemotherapy treatments. For one, the combination of D + Q with doxorubicin was shown mostly ineffective at further reducing tumor growths, as D + Q treatments were unable to eliminate doxorubicin-induced senescent cells [150] . However, it is likely that D + Q was injected too early (2 days) after the injection of doxorubicin, leaving no time for the induction of the senescent phenotype. In another study, ABT263 was used in combination with poly (ADP-ribose) polymerase 1 inhibitors (PARPi). This proved to be effective at reducing the growth of ovarian and breast tumors [151] . Hypothetically, we believe that the beneficial effect of a senolytic treatment in aged patients could help at different levels ( Figure 1 ). For one, the elimination of treatment-induced senescent cells slows down tumor growths by prevent- 

The administration of senolytic drugs is a promising strategy to prevent age-related pathologies. Two of the most tested senolytic treatments, D + Q and ABT263 (navitoclax), were, in fact, initially evaluated for their ability to kill tumor cells [144] [145] [146] . ABT263 has been in clinical trials, mostly for blood cancers, where it showed a limited effectiveness and severe treatment-induced thrombocytopenia [147, 148] . This led to the development of the analog venetoclax, which limits the occurrence of thrombocytopenia but is unfortunately ineffective as a senolytic drug [149] . Nonetheless, the repurposing of these drugs (perhaps at lower doses to limit the major side effects) or using one of the many novel senolytic drugs currently in development could, by eliminating senescent cells, reinvigorate immune cells and enhance the efficacy of immunotherapies. Few studies so far have explored the possibility of combining senolytic drugs with classical chemotherapy treatments. For one, the combination of D + Q with doxorubicin was shown mostly ineffective at further reducing tumor growths, as D + Q treatments were unable to eliminate doxorubicininduced senescent cells [150] . However, it is likely that D + Q was injected too early (2 days) after the injection of doxorubicin, leaving no time for the induction of the senescent phenotype. In another study, ABT263 was used in combination with poly (ADP-ribose) polymerase 1 inhibitors (PARPi). This proved to be effective at reducing the growth of ovarian and breast tumors [151] . Hypothetically, we believe that the beneficial effect of a senolytic treatment in aged patients could help at different levels ( Figure 1 ). For one, the elimination of treatment-induced senescent cells slows down tumor growths by preventing the direct mitogenic effect of the SASP on residual tumor cells [76] . Second, this effect could be indirect through the elimination of senescent cells from the TME, which could favor the tumor immune response. The reversal of myeloid cells skewing, which was demonstrated with ABT263, is another mechanism by which senolytics may improve immunotherapies [40] (Figure 1 ). 

Different preclinical studies have tried blocking proinflammatory cytokines, hoping to improve the efficacy of ICI [152] . Interestingly, most of the targeted cytokines overlapped with the SASP, supporting the hypothesis that these approaches can help suppress tumor growth in older patients [124] .

Very recently, a strategy focusing on blocking IL-6 to decrease the recruitment and the immunosuppressive ability of MDSC was tested [153] . However, this treatment failed to enhance the efficacy of PD-1-blocking antibodies in melanoma. The authors hypothesized that primary IL-6 signaling is necessary to activate immune cells. Nevertheless, this strategy may be more efficient in older patients, where the circulating level of IL-6 is higher [154] . To our knowledge, the preclinical evaluation of the combination of a senolytic drug with an ICI is lacking. Yet, other strategies looking to improve ICI have been recently tested and are discussed below.

Different preclinical studies have tried blocking proinflammatory cytokines, hoping to improve the efficacy of ICI [152] . Interestingly, most of the targeted cytokines overlapped with the SASP, supporting the hypothesis that these approaches can help suppress tumor growth in older patients [124] .

Very recently, a strategy focusing on blocking IL-6 to decrease the recruitment and the immunosuppressive ability of MDSC was tested [153] . However, this treatment failed to enhance the efficacy of PD-1-blocking antibodies in melanoma. The authors hypothesized that primary IL-6 signaling is necessary to activate immune cells. Nevertheless, this strategy may be more efficient in older patients, where the circulating level of IL-6 is higher [154] .

IL-10 is an important immunosuppressive cytokine secreted by MDSC [126] and T cells/Tregs isolated from aged mice [107, 108] . Other than inhibiting T-cell activation, IL-10 can boost the expression of PD-1 on tumor-infiltrated DCs and make tumor cells more resistant [155] . Interestingly, the blockade of IL-10 by using a neutralizing antibody decreases the accumulation of MDSC within the TME and enhances the efficacy of the anti-PD-1 therapy [155] . We speculate that blocking IL-10 pathways in association with ICI could be beneficial in aged mice, as they exhibit an increased systemic level of IL-10 [108].

C-C Motif Chemokine Ligand 2 (CCL2, or MCP-1 in mice) is a chemokine notably responsible for the recruitment of MDSC in the TME [126] . Hence, blocking the CCL2-CCR2 (CCL2 receptor) axis represents an interesting strategy to enhance the efficacy of immunotherapies. In this context, the median survival was found to be increased in a mouse model of glioma using a combination of CCR2 antagonist (CCX872) and PD-1-blocking antibodies [156] . In addition, a similar effect was observed with the same combination tested on several other tumor cell lines (bladder, melanoma pulmonary metastasis, and mammary tumors) [157] . As the level of CCL2/MCP-1 constantly increases during aging, blocking this pathway may alleviate the tumor resistance and improve the ICI efficacy [158] .

Sustained IFN type I exposure was shown to lead to the resistance of B16 melanoma tumors to ICI therapy through a mechanism involving the overexpression of several immune checkpoints (CD86, TNFRSF14, PDL1, and LGALS9) [159, 160] . In the same context, IFN type II was shown to increase the resistance of tumor cells to the cytotoxic action of CD8 T cells by enhancing the expression of SERPINB9 [161] . Nonetheless, the literature concerning the role of IFN type I is widely divergent. In fact, the secretion of IFN type I by infiltrated T cells within the TME elicits the apoptosis of MDSC and is associated with successful anti-PD-1 therapy [162] . Additionally, in aged mice (12 months), a treatment with a STING agonist (5,6-dimethylxanthenone-4-acetic acid (DMXAA)), used to enhance IFN type I signaling, can increase the efficacy of anti-PD-L1 and anti-CTLA-4 therapies [91] . Interestingly, the responses to IFN type I signaling are reduced in T cells isolated from older humans (65-85 vs. 20-35 years) [163] . Overall, it seems that short-term, but not chronic activation, of the IFN pathway in aged patients could be beneficial to improve the efficacy of immunotherapy.

Blocking TNFα is another promising strategy that was shown to enhance anti-PD-1 therapy in a mouse model of melanoma [164] . A phase 1 clinical trial based on this approach is currently active (TICIMEL-NCT03293784). In support of this approach, the level of circulating TNFα was found to be enhanced in aged mice and in a premature senescence model induced by mitochondrial dysfunction in T cells [165] .

In summary, the impact of senescence on many age-related pathologies, including cancer, is of growing interest. We believe that the age of patients at the time of treatment is poorly taken into consideration in preclinical research, despite an increasing amount of evidence highlighting its important role. It is clear that aging and senescence deeply modify the TME by favoring the accumulation of many types of immunosuppressive cells that will necessarily have an impact by making tumor cells more resistant and more prone to evade the immune system. As ICI fails in a substantial number of patients, identifying the mechanisms responsible for this failure is necessary to improve the efficacy of treatments. In the future, we believe it is crucial to include aged subjects in preclinical studies and, if possible, younger patients in clinical studies to thoroughly assess the impact of aging and senescence on the success of cancer treatments. The development of new senolytic treatments able to efficiently clear all types of senescent cells could represent a remarkably interesting strategy to improve immunotherapies. Data Availability Statement: All the data generated or analyzed during this study are included in this article.

The authors declare no conflict of interest.

Measuring population ageing: An analysis of the Global Burden of Disease Study

Cancer statistics for adults aged 85 years and older

Cancer Suppression at Old Age

Cellular senescence in aging and age-related disease: From mechanisms to therapy

From discoveries in ageing research to therapeutics for healthy ageing

Senescent Cells in Cancer Therapy: Friends or Foes? Trends Cancer

The serial cultivation of human diploid cell strains

A biomarker that identifies senescent human cells in culture and in aging skin in vivo

Hallmarks of Cellular Senescence

Cellular Senescence: Defining a Path Forward

Ink4a/Arf expression is a biomarker of aging

Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation

Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence

Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor

Cells 2021

Specific lipofuscin staining as a novel biomarker to detect replicative and stress-induced senescence. A method applicable in cryo-preserved and archival tissues

Extension of Life-Span by Introduction of Telomerase into Normal Human Cells

Ionizing radiation-induced long-term expression of senescence markers in mice is independent of p53 and immune status

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

The bystander effect contributes to the accumulation of senescent cells in vivo

Ageing hallmarks exhibit organ-specific temporal signatures

The Tabula Muris Consortium. A single-cell transcriptomic atlas characterizes ageing tissues in the mouse

Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders

An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA

Cells exhibiting strong p16 INK4a promoter activation in vivo display features of senescence

Naturally occurring p16I nk4a -positive cells shorten healthy lifespan

Embryonic senescent cells re-enter cell cycle and contribute to tissues after birth

Therapy-Induced Senescence in Cancer

Expression of the senescence marker p16INK4a in skin biopsies of acute lymphoblastic leukemia survivors: A pilot study

Young adult survivors of childhood acute lymphoblastic leukemia show evidence of chronic inflammation and cellular aging

Premature Aging in Young Cancer Survivors

The Achilles' heel of senescent cells: From transcriptome to senolytic drugs

Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors

Targeting senescent cells alleviates obesity-induced metabolic dysfunction

Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment

Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline

Inhibition of Bcl-2/xl With ABT-263 Selectively Kills Senescent Type II Pneumocytes and Reverses Persistent Pulmonary Fibrosis Induced by Ionizing Radiation in Mice

Cellular senescence mediates fibrotic pulmonary disease

Length-independent telomere damage drives post-mitotic cardiomyocyte senescence

Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice

Senolytics improve physical function and increase lifespan in old age

Fisetin is a senotherapeutic that extends health and lifespan

Identification and characterization of Cardiac Glycosides as senolytic compounds

Cardiac glycosides are broad-spectrum senolytics

Senolytic CAR T cells reverse senescence-associated pathologies

A decade of immune-checkpoint inhibitors in cancer therapy

Enhancement of antitumor immunity by CTLA-4 blockade

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Nivolumab plus Ipilimumab in Advanced Melanoma

Future Challenges in Cancer Resistance to Immunotherapy

A guide to cancer immunotherapy: From T cell basic science to clinical practice

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

The abscopal effect 67 years later: From a side story to center stage

Using immunotherapy to boost the abscopal effect

Abscopal Effect of Radiotherapy in the Immunotherapy Era: Systematic Review of Reported Cases

Men and mice: Relating their ages

Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model

Senescenceassociated β-galactosidase reveals the abundance of senescent CD8+ T cells in aging humans

Efficacy of immune checkpoint inhibitors and age in cancer patients

Cancer immunotherapy efficacy and patients' age: A systematic review and meta-analysis

Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer

Association of Age with Efficacy of Immunotherapy in Metastatic Melanoma

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Considerations for successful cancer immunotherapy in aged hosts: Ageing and cancer immunotherapy

A framework for advancing our understanding of cancer-associated fibroblasts

The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment

Bone marrow-derived fibroblasts are a functionally distinct stromal cell population in breast cancer

Adipocyte-Derived Fibroblasts Promote Tumor Progression and Contribute to the Desmoplastic Reaction in Breast Cancer

Mutual dependence of the MRTF-SRF and YAP-TEAD pathways in cancer-associated fibroblasts is indirect and mediated by cytoskeletal dynamics

Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner

CXCL1 induces senescence of cancer-associated fibroblasts via autocrine loops in oral squamous cell carcinoma

Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination

Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy

Senescent stroma promotes prostate cancer progression: The role of miR-210

Senescent fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging

Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis

Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression

Autologous humanized mouse models of iPSC-derived tumors allow for the evaluation and modulation of cancer-immune cell interactions

Unmasking senescence: Context-dependent effects of SASP in cancer

Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse

Changes in blood lymphocyte numbers with age in vivo and their association with the levels of cytokines/cytokine receptors

The effect of age on thymic function

Mechanisms underlying T cell ageing

Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus

The Changing Landscape of Naive T Cell Receptor Repertoire With Human Aging

Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age

Ionizing radiation-induced expression of INK4a/ARF in murine bone marrow-derived stromal cell populations interferes with bone marrow homeostasis

Characterization of age-associated exhausted CD8 + T cells defined by increased expression of Tim-3 andPD-1

Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer

Aging increases cell-to-cell transcriptional variability upon immune stimulation

Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?

Hallmarks of T cell aging

Expression of p16 INK4a in peripheral blood T-cells is a biomarker of human aging

Expression of p16 INK4a prevents cancer and promotes aging in lymphocytes

Restored immune cell functions upon clearance of senescence in the irradiated splenic environment

A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring

CD28 and CD57 define four populations with distinct phenotypic properties within human CD8 + T cells

Progressive decrease of CD8 high+ CD 28+ CD 57− cells with ageing

Mitochondrial mass governs the extent of human T cell senescence

Type 2 diabetes is associated with the accumulation of senescent T cells

Increased frequency of CD4 + CD57 + senescent T cells in patients with newly diagnosed acute heart failure: Exploring new pathogenic mechanisms with clinical relevance

Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia

CD57 + Memory T Cells Proliferate In Vivo. Cell

Emerging Functions of Regulatory T Cells in Tissue Homeostasis

Aging is associated with increased regulatory T-cell function

IL-10-producing Tfh cells accumulate with age and link inflammation with age-related immune suppression

senescence via the ROS axis during immunological aging

Aging of mice is associated with p16(Ink4a)-and β-galactosidase-positive macrophage accumulation that can be induced in young mice by senescent cells

Gitlin, I.I.; et al. p16(Ink4a) and senescence-associated β-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli

Tumor-Associated Macrophages: Recent Insights and Therapies. Front. Oncol. 2020, 10

Macrophage Depletion in Elderly Mice Improves Response to Tumor Immunotherapy

Aging Impairs the Ability of Conventional Dendritic Cells to Cross-Prime CD8+ T Cells upon Stimulation with a TLR7 Ligand

Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response

Neutrophil diversity and plasticity in tumour progression and therapy

Tumour-associated neutrophils in patients with cancer

IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis

Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma

Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway

Neutrophil extracellular traps kill bacteria

Neutrophil Extracellular Traps Induced by IL8 Promote Diffuse Large B-cell Lymphoma Progression via the TLR9 Signaling

CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression

Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression

Blood CD33(+)HLA-DR(−) myeloid-derived suppressor cells are increased with age and a history of cancer

A Role for Immature Myeloid Cells in Immune Senescence

Hara, E. p16 Ink4a and p21 Cip1/Waf1 promote tumour growth by enhancing myeloid-derived suppressor cells chemotaxis

Monitoring Tumorigenesis and Senescence In Vivo with a p16 INK4a -Luciferase Model

Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice

Expansion of myeloidderived suppressor cells with aging in the bone marrow of mice through a NF-κB-dependent mechanism

Mitigating Age-Related Immune Dysfunction Heightens the Efficacy of Tumor Immunotherapy in Aged Mice

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

Increased circulating myeloidderived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

B16 Murine Melanoma and Aging: Slower Growth and Longer Survival in Old Mice23

The effects of aging on tumor growth and angiogenesis are tumor-cell dependent

Altered Angiogenesis Underlying Age-Dependent Changes in Tumor Growth

Age-related tumor growth in mice is related to integrin α 4 in CD8 + T cells

The Aged Microenvironment Influences the Tumorigenic Potential of Malignant Prostate Epithelial Cells

Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors

Eph receptors and ephrins as targets for cancer therapy

Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL

Senolytic Cocktail Dasatinib+Quercetin (D+Q) Does Not Enhance the Efficacy of Senescence-Inducing Chemotherapy in Liver Cancer

Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence

Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment

IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma

Interleukin-6 in Aging and Chronic Disease: A Magnificent Pathway

IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer

CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas

Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy

Circulating levels of monocyte chemoattractant protein-1 as a potential measure of biological age in mice and frailty in humans

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade

Type I IFN protects cancer cells from CD8 + T cell-mediated cytotoxicity after radiation

Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer

Age-Associated Failure To Adjust Type I IFN Receptor Signaling Thresholds after T Cell Activation

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma

T cells with dysfunctional mitochondria induce multimorbidity and premature senescence